天域生物公告，董事长罗卫国因工作调整，申请辞去公司董事长、董事、审计委员会委员、提名委员会 委员、薪酬与考核委员会委员及战略与ESG委员会主任委员职务。截至本公告披露日，罗卫国持有公司 股份3725.18万股，占公司总股本比例为12.84%。公司董事会已推举孟卓伟代行董事长职责。 ...

证券代码：603717 证券简称：天域生物 公告编号：2026-004 天域生物科技股份有限公司 关于 2026 年度为合作养殖农户提供担保预计的 进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 本次担保 金额 | | 实际为养殖农户提 供的担保余额（不 含本次担保金额） | | 是否在前期 预计额度内 | 本次担保是 否有反担保 | | --- | --- | --- | --- | --- | --- | --- | | | 420.00 | 万元 | 1,490.00 | 万元 | 是 | 是 | | 被担保人名称 谭清华、张志红 （夫妻关系） | | | | | | | 累计担保情况 | 对外担保逾期的累计金额（万元） | / | | --- | --- | | 截至本公告日上市公司及其控股子 | | | 公司对外担保总额（万元） | 103,991.59 | | （实际发生的担保余额，不含本次） | | | 对外担保总额占上市公司最近一期 | 200.47 | | ...

证券代码：603717 证券简称：天域生物 公告编号：2026-003 天域生物科技股份有限公司 2026年第一次临时股东会决议公告 | 1、出席会议的股东和代理人人数 | 160 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 41,560,569 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 16.1207 | | 份总数的比例（%） | | (四) 表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况等。 本次股东会由公司董事会召集，过半数董事共同推举董事孟卓伟先生主持本 1 (一) 股东会召开的时间：2026 年 1 月 5 日 (二) 股东会召开的地点：上海市杨浦区国权北路 1688 号湾谷科技园 C4 幢二 层 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： 本次会议是否有否决议案：无 一、 会议召开和出席情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 次现场会议。本次会议采取现场记名投票与网络投票相结 ...

上海市锦天城律师事务所 关于天域生物科技股份有限公司 2026 年第一次临时股东会的 法律意见书 锦 天 城 律师事务 所 ALLBRIGHT LAW OFFICES 地址：上海市浦东新区银城中路 501 号上海中心 11、12 层 电话: 021-20511000 传真: 021-20511999 邮编: 200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于天域牛物科技股份有限公司 2026年第一次临时股东会的法律意见书 致:天域生物科技股份有限公司 上海市锦天城律师事务所(以下简称"本所")接受天域生物科技股份有限 公司(以下简称"公司") 委托. 就公司召开 2026年第一次临时股东会(以下 简称"本次股东会")的有关事宜,根据《中华人民共和国公司法》(以下简称 "《公司法》")《上市公司股东会规则》等法律、法规和其他规范性文件以及 《天域生物科技股份有限公司章程》(以下简称"《公司章程》")的有关规定, 出具本法律意见书。 为出具本法律意见书. 本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则(试行)》等规定,严格履行 了法定职责, ...

Core Viewpoint - Tianyu Biological (603717.SH) is currently trading at 7.68 yuan, reflecting a decline of 2.04% and is in a state of breaking its initial public offering price [1] Group 1: Company Overview - Tianyu Biological was previously known as Tianyu Ecology and will officially change its name on August 21, 2024, while retaining its stock code 603717 [1] - The company was listed on the Shanghai Stock Exchange on March 27, 2017, with an issuance of 43.1779 million shares at a price of 14.63 yuan per share [1] Group 2: Fundraising and Financials - The total amount raised from the initial public offering was 631.6927 million yuan, with a net amount of 570.1861 million yuan after expenses [2] - The total issuance costs for the IPO were 61.5066 million yuan, including an underwriting fee of 52.7196 million yuan [3] - Tianyu Biological's previous fundraising totaled 1.034 billion yuan, with a non-public offering of 48.35 million shares at a price of 8.32 yuan per share, raising 402.272 million yuan [4][5]

Group 1: Innovation in Pharmaceuticals - In 2025, China approved a record 76 innovative drugs, significantly surpassing the 48 approved in 2024, marking a historical high [1] - The total amount of foreign licensing transactions for innovative drugs in China exceeded $130 billion in 2025, with over 150 transactions, also a historical high [1] - Among the 76 approved innovative drugs, 47 are chemical drugs, 23 are biological products, and 6 are traditional Chinese medicines, with a high proportion of domestic innovations [1] Group 2: Drug Approval and Clinical Trials - China Medical's subsidiary Tianfang Pharmaceutical received approval for clarithromycin tablets, which passed the consistency evaluation for generic drugs [2] - Microchip Biotech announced that its CS08399 tablets for treating tumors with MTAP deficiency have had their clinical trial application accepted [3] - Frontier Biotech's FB7013 injection, targeting MASP-2 for IgA nephropathy, received acceptance for its clinical trial application, marking it as a first-in-class drug [4] Group 3: Capital Market Activities - Yifang Biotechnology submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as the exclusive sponsor [5] - Wanyi Medical also submitted a listing application to the Hong Kong Stock Exchange, with Guotai Junan International as the exclusive sponsor [6] Group 4: Corporate Investments and Acquisitions - Yunnan Baiyao plans to invest up to 45% of its net assets in financial products in 2026 [7] - Haili Biological's subsidiary intends to acquire 51% stakes in seven dental chain companies for 61.2 million yuan, expecting to increase revenue by approximately 100 million yuan [9] Group 5: Corporate Restructuring and Legal Matters - *ST Chang Pharmaceutical announced that its restructuring investors intend to terminate the restructuring investment agreement [10] - Zai Lab entered a global strategic cooperation and licensing agreement with AbbVie for the development and commercialization of ZG006, with potential milestone payments totaling up to $10.75 billion [11] - Tianyu Biotech's actual controller received a notice from the China Securities Regulatory Commission regarding an investigation into alleged illegal stock reduction [13]

公开信息显示，2022年3月3日，上交所下发《关于对天域生态环境股份有限公司控股股东罗卫国予以通 报批评的决定》。罗卫国与一致行动人持股比例因公司非公开发行股票被动稀释变动达到总股本8.33% 后又主动减持，未按规定及时履行相关权益变动披露义务，违反了上交所《股票上市规则》有关规定， 上交所对罗卫国作出予以通报批评的纪律处分决定。 （编辑：罗辑 审核：夏欣 校对：翟军） 中经记者 孙汝祥 夏欣 北京报道 天域生物（603717.SH）2025年12月31日披露，公司实际控制人罗卫国于近日收到中国证监会下发的 《立案告知书》。因罗卫国涉嫌违规减持天域生物股票，中国证监会决定对其立案。 天域生物方面在公告中表示，本次立案系对公司实际控制人的个人调查，与上市公司无关，不会对上市 公司及子公司生产经营活动产生影响。 ...

Group 1 - The chairman and actual controller of Tianyu Biological, Luo Weiguo, is under investigation by the China Securities Regulatory Commission (CSRC) for suspected illegal stock reduction [1][3] - Tianyu Biological announced that the investigation is related to Luo Weiguo's personal actions and will not affect the company's operations or subsidiaries [3] - As of the end of Q3 2025, Luo Weiguo holds 37.25 million shares, accounting for 12.84% of Tianyu Biological, making him the largest shareholder [3] Group 2 - Tianyu Biological has provided guarantees totaling 1.039 billion yuan, which is 200.22% of the company's most recent audited net assets [5] - The company signed a guarantee contract with Hubei Zhijiang Rural Commercial Bank to support cooperative breeding operations, with a maximum guarantee amount of 4.9 million yuan [5] - For the year 2026, Tianyu Biological plans to provide guarantees not exceeding 50 million yuan to breeding farmers, aligning with industry practices and supporting the company's strategic development [5] Group 3 - Tianyu Biological's main business focuses on three core sectors: ecological agriculture and animal husbandry, ecological energy, and ecological environment [6] - As of December 31, the stock price of Tianyu Biological was 7.84 yuan per share, with a total market capitalization of 2.3 billion yuan [7]

Core Viewpoint - Tianyu Biological's chairman, Luo Weiguo, is under investigation by the China Securities Regulatory Commission (CSRC) for suspected illegal stock reduction, which is a personal investigation and does not affect the company's operations [2][4][6][7]. Group 1: Investigation Details - The CSRC issued a notice of investigation (No. 0152025014) to Luo Weiguo regarding his alleged illegal reduction of Tianyu Biological's shares [4][6]. - Luo Weiguo holds 37,251,829 shares, accounting for 12.84% of the total shares, making him the largest shareholder of Tianyu Biological [7][8]. Group 2: Company Operations and Financials - As of December 31, 2025, Tianyu Biological's stock price was 7.84 yuan per share, with a total market capitalization of 2.3 billion yuan [12]. - The company has provided guarantees totaling 1.039 billion yuan, which is 200.22% of its most recent audited net assets, to support cooperative breeding operations [10]. - Tianyu Biological plans to provide up to 50 million yuan in guarantees for breeding farmers in 2026, aligning with industry practices and supporting its pig breeding business [10][11].

天域生物（603717）(603717.SH)发布公告，公司收到公司实际控制人罗卫国先生的通知，其于近日收 到中国证券监督管理委员会(以下简称"中国证监会")下发的《立案告知书》(编号：证监立案字 0152025014号)。因罗卫国先生涉嫌违规减持天域生物股票，根据《中华人民共和国证券法》《中华人 民共和国行政处罚法》等法律法规，中国证监会决定对其立案。 ...